Related Experiment Video
Updated: Oct 5, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis
Parisa Shamshiripour1,2, Mehdi Nikoobakht3, Zahra Mansourinejad4
1Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Background:
Gliomas are major challenges of neuro-oncology due to high mortality. Clinical applications of dendritic cells (DCs) have yielded promising results in the clinical trial pipelines over decades.
Research Design:
In this systematic review, we critically discuss the current status, future perspective, and challenges of DC therapy for gliomas . and summarize the study population, blinding, comparators, dosage, treatment regimens, efficacy, and safety issues of the clinical trials published on DC therapy for gliomas and also report the results of our meta-analysis on safety and immunological efficacy of DC therapy for gliomas.
Results:
The results of our meta-analysis indicated that the most frequent grade I/II adverse event (AE) reported in phase I or phase I/II trials was fatigue (∼16% and 24%). Moreover, in phase II trials, fatigue and cytopenia were the most common AEs (∼9% and 14%). Meanwhile, Grade III/IV AEs were rare . Moreover, our meta-analysis indicated ∼64% CD8+ T cells infiltration into tumor site after DC therapy and also ∼45% IFNγ increase.
Conclusions:
DC therapy could serve as a potential immunotherapy for gliomas; however, limitations exist to draw certain conclusions due to diversity of the criteria applied to assess clinical response and limited data on patients' survival.
Insights
Dendritic cell (DC) therapy shows potential for treating gliomas, with common side effects like fatigue. Further research is needed to confirm its efficacy and impact on patient survival.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Research
Background:
- Gliomas present significant challenges in neuro-oncology due to high mortality rates.
- Dendritic cell (DC) therapy has shown promise in clinical trials for various cancers over decades.
Purpose of the Study:
- To critically review the current status, future prospects, and challenges of DC therapy for gliomas.
- To summarize clinical trial data on DC therapy for gliomas, including efficacy and safety.
- To conduct a meta-analysis on the safety and immunological efficacy of DC therapy for gliomas.
Main Methods:
- Systematic review and meta-analysis of published clinical trials on DC therapy for gliomas.
- Critical discussion of study populations, blinding, comparators, dosage, treatment regimens, efficacy, and safety.
- Meta-analysis focused on safety and immunological outcomes.
Main Results:
- The most frequent adverse events (AEs) in Phase I/II trials were fatigue (16-24%) and cytopenia (9-14%) in Phase II.
- Grade III/IV AEs were rare.
- Meta-analysis showed approximately 64% CD8+ T cell infiltration and a 45% increase in IFN-γ post-DC therapy.
Conclusions:
- DC therapy represents a potential immunotherapy for gliomas.
- Limitations in clinical response assessment criteria and survival data hinder definitive conclusions.
- Further research is warranted to establish the full potential and limitations of DC therapy for glioma treatment.
